𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Rituximab/CHOP Induction Therapy in Newly Diagnosed Patients with Mantle-Cell Lymphoma1

Book ID
119615161
Publisher
CIG Media Group, LP.
Year
2000
Tongue
English
Weight
82 KB
Volume
1
Category
Article
ISSN
1526-9655

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

CHOP Chemotherapy plus Rituximab Compare
CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma
✍ Coiffier, Bertrand; Lepage, Eric; BriΓ¨re, Josette; Herbrecht, Raoul; Tilly, Herv πŸ“‚ Article πŸ“… 2002 πŸ› Massachusetts Medical Society 🌐 English βš– 116 KB

## Background The standard treatment for patients with diffuse large-B-cell lymphoma is cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). Rituximab, a chimeric monoclonal antibody against the CD20 B-cell antigen, has therapeutic activity in diffuse large-B-cell lymphoma. We conduct

Chemotherapy with rituximab followed by
Chemotherapy with rituximab followed by high-dose therapy and autologous stem cell transplantation in patients with mantle cell lymphoma
✍ Catherine Thieblemont; Daciana Antal; Laurence Lacotte-Thierry; Vincent Delwail; πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 English βš– 122 KB

## Abstract ## BACKGROUND The authors evaluated the efficacy of chemotherapy combined with rituximab followed by high‐dose therapy (HDT) plus autologous stem cell transplantation in patients with mantle cell lymphoma (MCL). ## METHODS This was a retrospective analysis of 34 patients who were tre